Cell & Gene Therapy Advancements Whitepaper

Considering the growing number of benefits that cell and gene therapies have provided when treating a wide range of conditions, researchers around the world have turned their attention to this next-generation class of biologics. From lower dosages to longer-lasting effects, the advantages of these therapies mean that scientists are working to accelerate them towards the clinic. In the original pieces listed below, experts in this whitepaper discuss the most recent progress in cell and gene therapies, from immuno-oncology to gene therapy for ocular conditions to stem cells. 

Included in this whitepaper:

• Lentiviral vectors: the key to cancer treatments that CAR T-cell therapy cannot reach?
  Professor Christian Brechot, TheraVectys
• How engineered RNA binding proteins delivered in vivo by gene therapy could treat myotonic dystrophy
  Dr Jim Burns, Locanabio
• Off-the-shelf T-cell therapy from gene edited stem cells
  Dr Jo Brewer, Adaptimmune
• Glycolytic-pathway inhibition and CTLA-4 blockade to improve immuno-oncology
  Dr Taha Merghoub, Memorial Sloan Kettering and Ludwig Cancer Research
• Challenges and opportunities in gene therapy development 
  Dr Carsten Brunn, Selecta Biosciences
• How RNA therapeutics can be used to treat retinitis pigmentosa
  Sahm Nasseri, PYC Therapeutics